Loyal
Loyal is a San Francisco-based, early stage biotech company working to develop a translational biology platform targeting metabolic aging biology in companion dogs. Companion dogs have a healthcare system second only to humans in sophistication and the regulatory process for new drug approvals for veterinary use share many similarities with human medicine. We are currently developing multiple safe (and we aim to prove via an FDA regulatory process) efficacious therapeutic strategies that we believe will increase the healthy lifespans of dogs.
Ridgeline Therapeutics:
Ridgeline just received the 2021 Catalyst Award from the US National Academy of Medicine (NAM) as part of their Healthy Longevity Global Competition. This award recognizes global innovators who are developing transformative treatments to extend healthspan and lifespan. At the Targeting Metabesity 2021 meeting, we will present the underlying science that has excited the NAM and NIH National Institutes of Aging and the drugs that have emerged from our research. Briefly, the enzyme NNMT is upregulated in aged skeletal muscle and excess adipose tissue. In both cases, NNMT upregulation disrupts cellular energetics and metabolic functions. In aged animal models, our NNMT inhibitor drugs can double muscle strength, size, and muscle stem cell regenerative capacity. In diet-induced obese animal models, our NNMT inhibitors prevent weight gain, stimulate lean muscle growth, and improve liver pathology, without affecting food intake.
Praetago
Praetego is developing first-in-class Advanced Glycation End-product inhibitors able to deter AGE formation at the initiation of pathology. Praetego’s candidates are designed to slow or prevent diseases driven by oxidative stress, essentially the chronic diseases of aging. This includes the highly burdensome diseases of Neurodegeneration & Alzheimer’s, Diabetic Microvascular Disease, and cardiovascular disease.
GlycanAge
GlycanAge is a healthy ageing company build on over three decades of research following 150,000 people, the GlycanAge test can measure your rate of ageing by looking at the immune system and balance of inflammation (inflammageing), through a very neglected molecule called glycans, specifically IgG glycosylation. GlycanAge has a number of other disease specific glycan based biomarkers in different stages of development, of which a menopause targeted biomarker may have the most promise.
Shift BioSciences
Cell reprogramming offers a path to comprehensive rejuvenation, but has a goldilocks problem. Too little and you have no rejuvenation, too much and you risk cancer. To fulfill its potential, cell-reprogramming must be made safe. Based on a novel application of machine learning, Shift Bioscience has identified an opportunity to tame cell reprogramming and safely reset cells and tissues back to a youthful state.
Biomarkers and Biological Clocks - a Panel Discussion
